MX2022011071A - Composiciones que mejoran la estabilidad del poxvirus. - Google Patents

Composiciones que mejoran la estabilidad del poxvirus.

Info

Publication number
MX2022011071A
MX2022011071A MX2022011071A MX2022011071A MX2022011071A MX 2022011071 A MX2022011071 A MX 2022011071A MX 2022011071 A MX2022011071 A MX 2022011071A MX 2022011071 A MX2022011071 A MX 2022011071A MX 2022011071 A MX2022011071 A MX 2022011071A
Authority
MX
Mexico
Prior art keywords
compositions
poxvirus
stability
improve
rhsa
Prior art date
Application number
MX2022011071A
Other languages
English (en)
Inventor
Markus Kalla
Katrine Kjaer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of MX2022011071A publication Critical patent/MX2022011071A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones acuosas que confieren estabilidad mejorada al poxvirus durante el almacenamiento, así como al uso de tales composiciones y métodos para prepararlas. Las composiciones comprenden albúmina de suero humano recombinante (rHSA), gelatina o arginina, o combinaciones de las mismas.
MX2022011071A 2020-03-12 2021-03-12 Composiciones que mejoran la estabilidad del poxvirus. MX2022011071A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20162856 2020-03-12
PCT/EP2021/056370 WO2021180943A1 (en) 2020-03-12 2021-03-12 Compositions improving poxvirus stability

Publications (1)

Publication Number Publication Date
MX2022011071A true MX2022011071A (es) 2022-09-23

Family

ID=69810726

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011071A MX2022011071A (es) 2020-03-12 2021-03-12 Composiciones que mejoran la estabilidad del poxvirus.

Country Status (11)

Country Link
US (1) US20230114464A1 (es)
EP (1) EP4117722A1 (es)
JP (1) JP7712284B2 (es)
KR (1) KR20220153587A (es)
CN (1) CN115243717A (es)
AU (1) AU2021233167A1 (es)
BR (1) BR112022017438A2 (es)
CA (1) CA3170701A1 (es)
IL (1) IL296250A (es)
MX (1) MX2022011071A (es)
WO (1) WO2021180943A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021205077A1 (en) 2020-04-09 2021-10-14 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
CN121218977A (zh) * 2023-05-17 2025-12-26 勃林格殷格翰国际有限公司 用以稳定基于病毒的治疗剂的调配物
AU2024273927A1 (en) * 2023-05-17 2025-11-06 Boehringer Ingelheim International Gmbh Formulations to stabilize virus-based therapeutics

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
WO2002042480A2 (en) 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
JP4500049B2 (ja) 2001-12-04 2010-07-14 バヴァリアン・ノルディック・アクティーゼルスカブ フラビウイルスｎｓ１サブユニットワクチン
NZ533302A (en) 2001-12-10 2005-11-25 Bavarian Nordic As Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions containing a disaaccharide and a pharmaceutically acceptable polymer i.e. dextran or polyvinylpyrrolidon (PVP)
EP1407006B9 (en) 2001-12-20 2006-10-18 Bavarian Nordic A/S Method for the recovery and purification of poxviruses from infected cells
UA85543C2 (ru) 2002-09-05 2009-02-10 Бавариан Нордик А/С Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных
JP2006508767A (ja) 2002-12-06 2006-03-16 ワールド・ハート・コーポレイション 小型拍動性移植可能心室補助デバイスおよび心室補助デバイスを制御する方法
CA2807534A1 (en) * 2003-02-25 2005-02-17 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
CA2531565C (en) 2003-07-22 2014-02-11 Vivalis Production of poxviruses with adherent or non adherent avian cell lines
JP2005040239A (ja) 2003-07-24 2005-02-17 Univ Nihon 画像処理方法、画像処理プログラム及びコンピュータ読取可能な記録媒体
WO2005066333A1 (en) 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
EP1807508A4 (en) 2004-11-05 2008-03-12 Us Gov Health & Human Serv METHODS FOR PREPARING CELLS AND VIRUSES
BRPI0618850A2 (pt) 2005-11-21 2011-09-13 Sanofi Pasteur Ltd formulações de estabilização para vìrus recombinantes
EP1979474B1 (en) 2006-01-05 2010-08-11 Transgene SA Avian telomerase reverse transcriptase
AU2007241405A1 (en) 2006-04-21 2007-11-01 Transgene S.A. HPV-18-based papillomavirus vaccine
ES2611975T3 (es) 2006-06-20 2017-05-11 Transgene S.A. Procedimiento para producir poxvirus y composiciones de poxvirus
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
CA2676149C (en) 2007-05-14 2016-06-21 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
ES2618490T3 (es) 2007-07-03 2017-06-21 Transgene Sa Estirpes celulares aviares inmortalizadas
CN102257134B (zh) 2008-02-12 2014-03-05 赛诺菲巴斯德有限公司 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法
CA2738024A1 (en) * 2008-09-24 2010-04-01 Medimmune, Llc Methods for purification of viruses
US7998488B2 (en) 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
KR20120026526A (ko) 2009-05-12 2012-03-19 트랜스진 에스.에이. 불멸화 조류 세포주 및 그의 용도
DK2432502T3 (en) 2009-05-20 2018-03-12 Aeras STABLE, SPRAY DRIED, IMMUNOGENE, VIRUS COMPOSITIONS
BR112012009450A2 (pt) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
CA2795047C (en) 2010-03-31 2019-04-09 Stabilitech Ltd. Stabilised liquid formulations
EP2898890B1 (en) 2010-03-31 2019-08-21 Stabilitech Biopharma Ltd Stabilisation of viral particles
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
AU2011281982B2 (en) 2010-07-20 2015-12-17 Bavarian Nordic A/S Method for harvesting expression products
AU2012251583B2 (en) 2011-05-05 2017-06-08 Albumedix Ltd. Albumin variants
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
BR112015002131B1 (pt) 2012-08-01 2022-11-01 Bavarian Nordic A/S Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
US20160222087A1 (en) 2013-09-13 2016-08-04 Novozymes Biopharma Dk A/S Albumin variants
WO2015136056A1 (en) 2014-03-12 2015-09-17 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
KR20190062617A (ko) 2014-09-03 2019-06-05 버베리안 노딕 에이/에스 면역 반응을 증대시키기 위한 방법 및 조성물
BR112017003891A2 (pt) 2014-09-03 2017-12-26 Bavarian Nordic As métodos e composições para induzir imunidade protetora contra infecção por filovírus
KR102812180B1 (ko) 2014-09-03 2025-05-23 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라 (mva) 필로바이러스 백신
DK3226894T3 (da) 2014-12-01 2019-10-21 Transgene Sa Stabile flydende vacciniavirus-formuleringer
WO2016202828A1 (en) 2015-06-15 2016-12-22 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
HUE059343T2 (hu) 2016-01-29 2022-11-28 Bavarian Nordic As Rekombináns, módosított Ankara Vaccinia vírus (MVA) és ló encephalitis vírus oltóanyag
US10517944B2 (en) 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
EP3429345B1 (en) 2016-10-04 2019-09-11 Albumedix Ltd. Uses of recombinant yeast-derived serum albumin
KR102658198B1 (ko) 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스 함유 조성물

Also Published As

Publication number Publication date
EP4117722A1 (en) 2023-01-18
WO2021180943A1 (en) 2021-09-16
BR112022017438A2 (pt) 2022-10-18
JP7712284B2 (ja) 2025-07-23
AU2021233167A1 (en) 2022-09-22
US20230114464A1 (en) 2023-04-13
CN115243717A (zh) 2022-10-25
KR20220153587A (ko) 2022-11-18
CA3170701A1 (en) 2021-09-16
JP2023516201A (ja) 2023-04-18
IL296250A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
MX2022011071A (es) Composiciones que mejoran la estabilidad del poxvirus.
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
MX2021003475A (es) Metodos de purificacion de proteinas.
CL2018002825A1 (es) Vacuna contra vrs
UY37997A (es) Agentes antivirales contra la hepatitis b
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
PH12020551637A1 (en) Additives for protein formulations to improve thermal stability
CY1124237T1 (el) Υγρο σκευασμα νευροτοξινης σταθεροποιημενο με τρυπτοφανη ή τυροσινη
EA202092464A1 (ru) Способы получения стабильных композиций на основе белков
AR118536A1 (es) Composiciones y métodos para estabilizar formulaciones que contienen proteína
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
MX2024010373A (es) Metodos y composiciones para el tratamiento de la hipertension pulmonar.
MX383330B (es) Particula tipo virus de flavivirus.
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
EA202192925A1 (ru) Твердые формы ингибитора glyt1
BR112022008497A2 (pt) Derivados terapêuticos da interleucina-22
MX2016012447A (es) Formulaciones de factor ix liofilizadas.
CO2020013690A2 (es) Composiciones y métodos para el tratamiento de la distrofia macular
AR132981A1 (es) Proteínas rsv-f sustituidas con cisteína
PE20190966A1 (es) Factor viii direccionado a los globulos rojos y metodo para su uso
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
EA201992626A1 (ru) Способы и композиции для лечения аллергических заболеваний глаз
AR092691A1 (es) Composicion farmaceutica que comprende rebamipida
ECSP24012819A (es) Proteínas actrii y usos de las mismas
PH12022550238A1 (en) Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations